Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study.
antirheumatic agents
arthritis
biological therapy
psoriatic
Journal
RMD open
ISSN: 2056-5933
Titre abrégé: RMD Open
Pays: England
ID NLM: 101662038
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
13
11
2020
revised:
26
01
2021
accepted:
27
01
2021
entrez:
17
2
2021
pubmed:
18
2
2021
medline:
1
9
2021
Statut:
ppublish
Résumé
To evaluate in a multicentric Italian cohort of patients with psoriatic arthritis (PsA) on secukinumab followed for 24 months: (1) the long-term effectiveness and safety of secukinumab, (2) the drug retention rate and minimal disease activity (MDA), (3) differences in the outcomes according to the biological treatment line: biologic-naïve patients ( Consecutive patients with PsA receiving secukinumab were evaluated prospectively. Disease characteristics, previous/ongoing treatments, comorbidities and follow-up duration were collected. Disease activity/functional/clinimetric scores and biochemical values were recorded at baseline (T0), 6(T6), 12(T12) and 24(T24) months. Effectiveness was evaluated overtime with descriptive statistics; multivariate Cox and logistic regression models were used to evaluate predictors of drug-discontinuation and MDA at T6. Infections and adverse events were recorded. 608 patients (41.28% men; mean (SD) age 52.78 (11.33)) were enrolled; secukinumab was prescribed as first-line biological treatment in 227 (37.34%) patients, as second (or more)-line biological treatment in 381 (62.66%). Effectiveness of secukinumab was shown with an improvement in several outcomes, such as Ankylosing Spondylitis Disease Activity Score (T0=3.26 (0.88) vs T24=1.60 (0.69) ;p=0.02) and Disease Activity Index for Psoriatic Arthritis (T0=25.29 (11.14) vs T24=7.69 (4.51); p<0.01). At T24, In a real-life clinical setting, secukimumab proved safe and effective in all PsA domains, with notable drug retention rate.
Identifiants
pubmed: 33593933
pii: rmdopen-2020-001519
doi: 10.1136/rmdopen-2020-001519
pmc: PMC7888309
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
secukinumab
DLG4EML025
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Raffaele Scarpa
(R)
Antonio Marchesoni
(A)
Carlo Salvarani
(C)
Salvatore d'Angelo
(S)
Alberto Cauli
(A)
Ennio Lubrano
(E)
Roberta Ramonda
(R)
Antonio Carriero
(A)
Maria Sole Chimenti
(MS)
Angelo Semeraro
(A)
Leonardo Santo
(L)
Mariagrazia Lorenzin
(M)
Augusta Ortolan
(A)
Andrea Doria
(A)
Elena Fracassi
(E)
Giulia Virelli
(G)
Marco Masia
(M)
Rosalinda Fanizzi
(R)
Elisa Visalli
(E)
Giorgio Amato
(G)
Antonio Carletto
(A)
Rosario Foti
(R)
Luisa Costa
(L)
Desiati Francesca
(D)
Giulia Lavinia Fonti
(GL)
Nicolò Girolimetto
(N)
Fabio Massimo Perrotta
(FM)
Emanuela Praino
(E)
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: RR has received honoraria and speaker fees from Novartis, AbbVie, Pfizer, MSD, Janssen. AM has received honoraria and speaker fees from AbbVie, Pfizer, MSD, UCB, Novartis, Janssen, Eli-Lilly. LS speaker from Jansen, Novartis, Pfizer, UCB, MSD, Sanofi.
Références
Rheumatology (Oxford). 2014 May;53(5):875-81
pubmed: 24407233
Int J Mol Sci. 2018 Feb 09;19(2):
pubmed: 29425183
Lancet. 2015 Sep 19;386(9999):1137-46
pubmed: 26135703
Clin Drug Investig. 2019 Dec;39(12):1205-1212
pubmed: 31549346
Arthritis Care Res (Hoboken). 2018 Oct;70(10):1529-1535
pubmed: 29409133
Ann Rheum Dis. 2020 Dec 17;:
pubmed: 33334727
Arthritis Rheumatol. 2016 May;68(5):1060-71
pubmed: 26749174
Arthritis Care Res (Hoboken). 2010 Jul;62(7):965-9
pubmed: 20589696
J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1507-1514
pubmed: 29444376
Ann Rheum Dis. 2020 Jun;79(6):700-712
pubmed: 32434812
Clin Exp Rheumatol. 2020 Jan-Feb;38(1):107-114
pubmed: 31287400
Rheumatology (Oxford). 2020 Sep 1;59(9):2455-2461
pubmed: 31960053
Nat Med. 2012 Jul 01;18(7):1069-76
pubmed: 22772566
Ann Rheum Dis. 2019 Apr;78(4):473-479
pubmed: 30674475
Ann Rheum Dis. 2016 Apr;76(4):673-680
pubmed: 27613807
Front Med (Lausanne). 2020 Jun 19;7:288
pubmed: 32637422
Reumatol Clin. 2019 Sep 3;:
pubmed: 31492601
Clin Exp Rheumatol. 2017 Nov-Dec;35(6):991-1010
pubmed: 29185959
J Am Acad Dermatol. 2019 Jul;81(1):173-178
pubmed: 30914343
J Rheumatol. 2020 Jun 1;47(6):854-864
pubmed: 31615919
Drugs. 2014 Mar;74(4):423-41
pubmed: 24566842
ACR Open Rheumatol. 2020 Jan;2(1):18-25
pubmed: 31943974
Rheumatol Int. 2014 Feb;34(2):227-34
pubmed: 24114527
Clin Exp Rheumatol. 2019 Mar-Apr;37(2):342-343
pubmed: 30620295
J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1693-1699
pubmed: 28602039
Arthritis Res Ther. 2013 Sep 26;15(5):R136
pubmed: 24286492
Clin Rheumatol. 2019 Sep;38(9):2355-2362
pubmed: 31264033
Clin Rheumatol. 2018 Feb;37(2):397-405
pubmed: 29302829
Int J Immunopathol Pharmacol. 2015 Dec;28(4):479-87
pubmed: 26384393
Arthritis Res Ther. 2014 Aug 22;16(4):426
pubmed: 25146432
J Am Acad Dermatol. 2019 Aug;81(2):427-432
pubmed: 30872150
Semin Arthritis Rheum. 2020 Dec;50(6):1494-1499
pubmed: 32145969
J Dermatolog Treat. 2019 Aug;30(5):424-429
pubmed: 30244618
Front Pharmacol. 2019 Aug 06;10:872
pubmed: 31447673
Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii14-7
pubmed: 15708927
Rheumatology (Oxford). 2018 Oct 1;57(57 Suppl 7):vii54-vii58
pubmed: 30289534
Rheum Dis Clin North Am. 2015 Nov;41(4):545-68
pubmed: 26476218
Ann Rheum Dis. 2012 Mar;71(3):319-26
pubmed: 21803753
Lancet. 2020 May 9;395(10235):1496-1505
pubmed: 32386593
Arthritis Rheum. 2006 Aug;54(8):2665-73
pubmed: 16871531
Nat Rev Rheumatol. 2017 Nov 21;13(12):731-741
pubmed: 29158573
Rheumatology (Oxford). 2017 Nov 1;56(11):1993-2003
pubmed: 28968735
J Am Acad Dermatol. 2019 Jul;81(1):273-275
pubmed: 30790602
N Engl J Med. 2015 Oct;373(14):1329-39
pubmed: 26422723
Drugs. 2016 Apr;76(6):663-73
pubmed: 26957495
Expert Opin Biol Ther. 2020 Jul;20(7):813-821
pubmed: 32401062
Ann Rheum Dis. 2019 Nov;78(11):1536-1544
pubmed: 31431486
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):1161-1173
pubmed: 31785165
Int J Dermatol. 2019 Jun;58(6):631-641
pubmed: 30973647
Ann Rheum Dis. 2018 Jan;77(1):3-17
pubmed: 28684559
Br J Dermatol. 2021 Mar;184(3):425-436
pubmed: 32479641
Ther Adv Musculoskelet Dis. 2018 Sep 06;10(9):169-180
pubmed: 30210583
Immunol Res. 2015 Feb;61(1-2):147-53
pubmed: 25395342
Front Pharmacol. 2019 Dec 13;10:1497
pubmed: 31920675
J Rheumatol. 2016 Sep;43(9):1713-7
pubmed: 27307536
Arthritis Res Ther. 2019 May 2;21(1):111
pubmed: 31046809
Semin Arthritis Rheum. 2018 Aug;48(1):28-34
pubmed: 29398124
Arthritis Res Ther. 2019 Dec 4;21(1):266
pubmed: 31801620
RMD Open. 2018 Aug 13;4(2):e000723
pubmed: 30167329
N Engl J Med. 2014 Jul 24;371(4):326-38
pubmed: 25007392
Arthritis Care Res (Hoboken). 2017 Mar;69(3):347-355
pubmed: 27696786
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S64-85
pubmed: 22588772
J Autoimmun. 2010 May;34(3):J314-21
pubmed: 20034760